PCV13 [pneumococcal 13-valent conjugate vaccine], or cohort 3: PPSV23 followed by or preceded by PCV13, PPSV23 preceded by PCV15 [pneumococcal 15-valent conjugate vaccine], or PCV15 alone).

Capvaxive is a pneumococcal vaccine specifically designed to help protect adults ... for more cases of IPD in adults compared to PCV20 (pneumococcal 20-valent conjugate vaccine), as shown in these ...

Merck MRK announced that the European Commission (“EC”) has approved its 21-valent pneumococcal conjugate vaccine (“PCV”), Capvaxive, for the prevention of invasive pneumococcal disease ...

Babies treated with antibiotics in the first few weeks of their life are likely to show weaker immune responses to essential ...

Immunization programs save millions of lives every year by protecting against preventable diseases. The immune response to ...

To protect your child, their doctor will give them the pneumococcal conjugate vaccine (PCV ... was approved in 2000, and ...

The 13-valent pneumococcal conjugate vaccine (PCV13) has obtained the corresponding drug production license and has submitted a registration application to the National Medical Products Administration ...

The 15-valent conjugate vaccine was at least as effective ... to steal a march on Pfizer in the large paediatric pneumococcal vaccine category, as its rival is around a year away from reporting ...

The pneumococcal conjugate vaccine – codenamed PCV21 ... Pfizer's Prevnar franchise dominates the child and adult pneumococcal vaccine category, with sales of $4.85 billion in the first nine ...

It develops broad-spectrum conjugate and novel protein vaccines ... Vaxcyte recently showed data suggesting that their pneumococcal vaccine is better than the current vaccines on the market ...